文献速递心律失常

房颤患者左心耳封堵术后抗栓治疗策略的真实世界分析

Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

基于美国LAAO注册研究2016-2018年31,994例成功置入Watchman装置的患者,仅12.2%完全遵循 pivotal 试验的术后方案。出院时华法林单药或DOAC单药较华法林联合阿司匹林与45天及6个月不良事件风险更低。

要点

  • 临床实践中仅12.2%患者完全遵循 pivotal 试验术后方案,最常见偏离为出院抗栓药物选择。
  • 出院华法林单药(HR 0.692)或DOAC单药(HR 0.731)较华法林联合阿司匹林显著降低45天不良事件风险。
  • 华法林单药在6个月随访时仍保持较低风险。

核心结论

  • 当代美国实践中,医生很少完全采用FDA批准的Watchman pivotal试验术后治疗方案。
  • 出院时使用华法林或DOAC而不联用阿司匹林与较低的不良结局风险相关。

研究设计与样本

  • 基于美国国家心血管数据注册LAAO注册研究,纳入2016-2018年成功置入Watchman装置的患者31,994例。
  • 评估术后完整方案(标准化随访、影像学及抗栓药物)的依从性,并采用多变量Cox脆弱回归比较不同出院抗栓策略在45天和6个月的不良事件风险。

主要发现

  • 仅12.2%患者接受pivotal试验研究的完整术后治疗方案,最常见偏离为出院抗栓药物。
  • 最常见出院药物策略:华法林联合阿司匹林36.9%、DOAC联合阿司匹林20.8%、华法林单药13.5%、DOAC单药12.3%、双联抗血小板治疗5.0%。
  • 多变量Cox脆弱回归中,与华法林联合阿司匹林相比,华法林单药(HR 0.692;95%CI 0.569-0.841)和DOAC单药(HR 0.731;95%CI 0.574-0.930)的45天任何不良事件调整风险显著更低。
  • 华法林单药在6个月随访时仍保持较低风险。

临床怎么用

  • Watchman置入后出院可考虑华法林或DOAC单药抗栓,而不联用阿司匹林,以降低不良事件风险。
  • 需注意真实世界中多数患者未完全遵循 pivotal 试验术后方案,抗栓策略选择存在较大变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used specific postprocedure treatment protocols. OBJECTIVES: This study sought to evaluate patterns of postprocedure care after LAAO with the Watchman device in clinical practice and compare the risk of adverse events for different discharge antithrombotic strategies. METHODS: We evaluated patients in the LAAO Registry of the National Cardiovascular Data Registry who underwent LAAO with the Watchman device between 2016 and 2018. We assessed adherence to the full postprocedure trial protocol including standardized follow-up, imaging, and antithrombotic agents and then evaluated the most commonly used antithrombotic strategies and compared the rates and risk of adverse events at 45 days and 6 months by means of multivariable COX frailty regression. RESULTS: Among 31,994 patients undergoing successful LAAO, only 12.2% received the full postprocedure treatment protocol studied in pivotal trials; the most common protocol deviations were with discharge antithrombotic medications. The most common discharge medication strategies were warfarin and aspirin (36.9%), direct oral anticoagulant (DOAC) and aspirin (20.8%), warfarin only (13.5%), DOAC only (12.3%), and dual antiplatelet therapy (5.0%). In multivariable Cox frailty regression, the adjusted risk of any adverse event through the 45-day follow-up visit were significantly lower for discharge on warfarin alone (HR: 0.692; 95% CI: 0.569-0.841) and DOAC alone (HR: 0.731; 95% CI: 0.574-0.930) compared with warfarin and aspirin. Warfarin alone retained lower risk at the 6-month follow-up. CONCLUSIONS: In contemporary U.S. practice, practitioners rarely used the full U.S. Food and Drug Administration-approved postprocedure treatment protocols studied in pivotal trials of the Watchman device. Discharge after implantation on warfarin or DOAC without concomitant aspirin was associated with lower risk of adverse outcomes.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Freeman, Higgins, Wang, et al. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2022. PMID: 35512858. doi:10.1016/j.jacc.2022.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。